静脉铁剂与口服铁剂在血液透析贫血患者临床治疗中的应用价值

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (29 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application value of intravenous iron and oral iron in the clinical treatment of hemodialysis (HD) anemia.Methods A total of 125 patients with HD anemia admitted to our hospital from January 2018 to May 2019 were selected as the study objects.They were divided into vein group (n=62) and oral group (n=63)according to the random number table method.The oral group was treated with Polysaccharide Iron Complex Capsules,the vein group was treated with Sucrose Iron injection.The levels of hemoglobin (Hb), serum ferritin (SF) before and after treatment were compared between the two groups.Results After treatment, the levels of Hb and SF in venous group were higher than those in oral group, the differences were statistically significant (P＜0.05).The total effective rate of vein group was 95.16%, which was higher than that of oral group (80.95%), the difference was statistically significant (P＜0.05).The incidence of complications in vein group was 4.84%, which was lower than that in control group(17.46%), the difference was statistically significant (P＜0.05).Conclusion In the treatment of HD anemia related patients, intravenous iron treatment can effectively improve the level of Hb and SF in the course of treatment, improve the clinical treatment effect of patients, reduce the incidence of complications, and the effect is ideal.

Key words： Intravenous iron Oral iron Hemodialysis Peritoneal dialysis Anemia patients Therapeutic value

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YE Shui-lian
	HUANG Yong-hong

Cite this article:

YE Shui-lian,HUANG Yong-hong. Application value of intravenous iron and oral iron in the clinical treatment of hemodialysis anemia[J]. 中国当代医药, 2020, 27(11): 56-58.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I11/56

[1]	白荷荷，聂晓静.王园姬.297例重组人促红素及铁剂治疗血液透析肾性贫血的合理性评价[J].药物流行病学杂志，2018，12（6）：117-119.
[2]	樊迪，路万虹，杨悦，等.促红细胞生成素及铁剂治疗肾性贫血的合理性评价[J].西北药学杂志，2016，31（3）：305-308
[3]	Coronado Daza J，Martí-Carvajal AJ，Ariza García A，et al.Early versus delayed erythropoietin for the anaemia of endstage kidney disease[J].Cochrane Database Syst Rev，2015（12）：CD011122.
[4]	Zebrowski P，Mieczkowski M.Erythropoietin stimulating agents in chronic kidney disease：indications and contraindications[J].Wiad Lek，2016，69（5）：753-755.
[5]	Locatelli F，Del Vecchio L.New strategies for anaemia management in chronic kidney disease[J].Contrib Nephrol，2017，189：184-188.
[6]	Rostoker G，Vaziri ND，Fishbane S.Iatrogenic iron over-load in dialysis patients at the beginning of the 21stcentury[J].Drugs，2016，76（7）：741-757.
[7]	张贵兵，陈三军.蔗糖铁联合促红细胞生成素治疗维持性血液透析肾性贫血[J].药物流行病学杂志，2015，24（5）：271-273.
[8]	李晓燕，冯要菊.左卡尼汀联合促红细胞生成素纠正维持性血液透析患者肾性贫血的效果及对内皮素和左室重构的影响[J].药物评价研究，2017，40（4）：521-524.
[9]	王媛媛.重组人促红素与蔗糖铁联合左卡尼丁对尿毒症维持性血液透析肾性贫血患者的疗效分析[J].河南医学研究，2018，27（7）：165-166.
[10]	庄洁.蔗糖铁联合左卡尼汀治疗维持性血液透析患者肾性贫血的疗效观察[J].临床医药杂志，2017，4（60）：11 831-11 832.
[11]	贾建设.左卡尼汀联合促红细胞生成素治疗肾性贫血患者临床效果观察[J].河南医学研究，2017，26（4）：657-658.
[12]	周麟，李向东，赵明.左卡尼汀联合促红细胞生成素对尿毒症肾性贫血及左室重构的影响[J].中国药业，2018，27（9）：54-57.
[13]	黄美英，王洁.蔗糖铁注射液联合左卡尼汀及促红细胞生成素治疗肾性贫血的疗效观察[J].临床合理用药杂志，2017，10（28）：65-66.
[14]	白荷荷，聂晓静，王园姬.297例重组人促红素及铁剂治疗血液透析肾性贫血的合理性评价[J].药物流行病学杂志，2018，27（6）：392-395.
[15]	沈江山，尹金凤，万来彪.重组人促红细胞及铁剂治疗血液透析肾性贫血的临床观察[J].临床合理用药，2019，12（19）：87-88.